Sign In
Buy VERX
$12.79
-1.06 (-7.65%)
At Close: Jun 03, 2026
Madrigal Pharmaceuticals Could Become The Next Vertex
09:40pm, Tuesday, 02'nd Jun 2026
Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
12:10pm, Tuesday, 02'nd Jun 2026
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
10:25am, Monday, 01'st Jun 2026
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
Vertex to Present at the 46th Annual William Blair Growth Stock Conference
08:00am, Monday, 01'st Jun 2026
KING OF PRUSSIA, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that Chris Young, Presid
New Vertex Research Highlights Rising Revenue Risk from IT, Tax, and Finance Misalignment
07:00am, Tuesday, 19'th May 2026
Only 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical Only 12% of organizations globally have fully integrated tax technology,
Vertex Q1 Earnings Call Highlights
03:12am, Saturday, 09'th May 2026
Vertex NASDAQ: VERX reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as management outlined a cost-reduction program intended to fund investm
Vertex: Profitability Ramps Up As Company Drives Efficiency Initiatives
07:07pm, Friday, 08'th May 2026
Vertex remains a "Buy" as its tax compliance software business shows resilience amid broad SaaS sector weakness. Despite a ~20% YTD and 60% 1-year decline, VERX delivered a strong Q1 beat-and-raise, w
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
03:01pm, Thursday, 07'th May 2026
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
10:31am, Thursday, 07'th May 2026
While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to
Vertex (VERX) Tops Q1 Earnings and Revenue Estimates
09:56am, Thursday, 07'th May 2026
Vertex (VERX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Announces First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
KING OF PRUSSIA, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading provider of enterprise compliance technology for global commerce, toda
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
12:45pm, Wednesday, 06'th May 2026
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
02:15pm, Tuesday, 05'th May 2026
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
04:04pm, Monday, 04'th May 2026
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
